Equities

Sequana Medical NV

Sequana Medical NV

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.33
  • Today's Change-0.03 / -2.21%
  • Shares traded10.24k
  • 1 Year change-57.53%
  • Beta0.7741
Data delayed at least 15 minutes, as of Jul 05 2024 15:57 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

  • Revenue in EUR (TTM)712.17k
  • Net income in EUR-32.56m
  • Incorporated2018
  • Employees62.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MediGene AG-100.00bn-100.00bn35.66m86.00--1.49----------0.8144-----------22.31---25.28--90.15---123.17----0.1228---80.69-4.89-94.20---8.12--
Saniona AB1.82m-7.33m35.94m23.00--14.98--19.71-1.09-1.090.26290.24510.1726--5.63900,521.80-69.41-59.16-127.89-70.15-136.88-970.05-402.20-1,483.55---3.850.71--10.19-21.0554.71---34.94--
Xbrane Biopharma AB16.81m-31.80m36.35m75.00--1.05--2.16-1.33-1.580.69780.25770.24651.34332.122,053,430.00-46.63-40.98-78.01-67.2415.43---189.18-364.401.43-31.130.3693--314.3363.42-91.10--60.02--
Mendus AB (publ)0.00-9.43m36.80m28.00--0.5329-----1.59-1.590.0015.570.00----0.00-16.09-18.84-17.35-20.21-------28,474.53---150.860.0348---100.00--26.78------
genOway SA20.05m1.57m38.21m133.0023.132.209.521.910.17820.17822.281.880.6190.7733.10150,724.704.840.21666.640.304895.8294.827.820.41771.9528.110.3047--17.5513.16101.5522.35----
Fermentalg SA4.06m-14.15m38.39m62.00--0.7385--9.46-0.3176-0.31760.09170.60330.07530.5333.3565,451.61-24.63-21.94-26.79-24.7113.2114.73-327.08-248.953.53-60.940.3323---46.9475.18-43.29---10.93--
Lytix Biopharma AS348.57k-7.68m38.91m10.00--7.12--111.63-2.16-2.160.09811.260.0368--0.4091399,100.00-80.96-56.91-94.07-65.83-----2,202.36-771.78----0.0095---63.8263.94-56.77------
Bergenbio ASA45.50k-13.50m39.12m16.00--330.18--859.77-0.1849-0.18490.00030.03470.0047--0.048520,840.00-139.81-66.15-275.19-78.74-----29,658.54-11,419.44----0.00---9.00-31.4336.98------
Incanthera PLC0.00-1.74m39.30m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Abionyx Pharma SA4.64m-3.52m39.79m61.00--4.98--8.58-0.121-0.1210.15810.2460.302721.864.2076,694.22-22.95-18.82-32.52-28.8713.3214.32-75.82-128.541.70--0.2997---11.6592.8416.36--41.40--
Sequana Medical NV712.17k-32.56m40.07m62.00------56.27-1.22-1.220.0266-0.69050.03941.999.0811,486.61-180.28-170.42-4,305.25-660.97-586.32-255.63-4,572.45-3,072.270.2055-8.92-----22.82-7.10-5.85--79.05--
Novacyt SA9.30m-29.90m41.10m222.00--0.324--4.42-0.4234-0.42470.13171.800.05281.330.262241,907.38-16.9617.69-20.7123.8243.2162.82-321.4023.874.98-79.020.00360.00-77.2813.49-269.46---13.46--
Hamlet BioPharma AB0.00-2.94m41.62m7.00--8.17-----0.2326-0.23260.000.4530.00-------63.45-83.52-69.09-107.84------------0.00-------18.87--78.01--
Arecor Therapeutics PLC5.41m-10.11m42.53m50.00--3.78--7.87-0.2793-0.27930.14930.31110.2462--1.3391,460.00-46.06---60.53-------187.05--2.02--0.0343--90.30--7.62------
Sareum Holdings Plc0.00-5.03m42.74m5.00--56.45-----0.0614-0.06140.000.00590.00----0.00-160.20-71.41-195.05-81.48-------19,709.24---6.610.00-------46.96------
Initiator Pharma A/S0.00-3.02m43.95m3.00--14.67-----0.6301-0.63010.000.6430.00----0.00-70.60-68.27-73.77-74.02------------0.00------27.95------
Data as of Jul 05 2024. Currency figures normalised to Sequana Medical NV's reporting currency: Euro EUR

Institutional shareholders

0.39%Per cent of shares held by top holders
HolderShares% Held
LSP Advisory BVas of 31 Dec 2023116.58k0.39%
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.